Iowa Medical Society Opioid Summit
The IMS Opioid Summit will give practical and productive response to Iowa’s rise in opioid use disorder.
MAT (Medical Assisted Treatment) Waiver Training will be provided by Alison Lynch, MD, University of Iowa. Shockingly few Iowa physicians have obtained a MAT waiver; increased training opportunities are a crucial step toward expanding patient access across the state.
Mornings sessions will include the 4 hour live required portion of MAT waiver training. Once participants complete this step they will be eligible to access the second, online portion of MAT. Corresponding this session will be CDC Prescribing Guidelines Training. Provided by Lee Kral, PharmD, BCBS, University of Iowa.
Afternoon sessions: National and local experts will convene to provide insights on techniques to combat Iowa’s opioid abuse disorder.
Professional Practice Gap
On July 1, 2018, a new law was passed that required all those prescribing opioids to complete training on the CDC guidelines. In addition, Iowa is seeing an uptick in the number of patients suffering from substance abuse disorder and physicians and non-physicians providers are equipped with the knowledge to proper treat these patients.
- Describe the specific application of the CDC opioid guidelines and the controversy they have caused.
- Apply the guidelines in a practical way to a patient clinical scenario.
- Educate a patient regarding long-term opioid safety.
- Develop a tapering plan for a given patient.
- Explore the impact of the opioids crisis on the U.S. and Iowa.
- Discuss best-practices used in Iowa and in the U.S.
- Describe how an addict is “made.”
- Describe the healthcare experience from the addicts perception.
- Discuss medical models for treating addiction.
- State the importance of counseling/therapy in conjunction with Medication Assisted Treatment (MAT).
- Define is MAT.
- State the differences between the Data Waiver, Medication Unit and Full Opioid Treatment Program.
- Opportunities for partnering for success against the opioid epidemic – opening a med unit, outreach, etc.
- State the difference between tolerance, physical dependence and addiction.
- Distinguish the specific liability risks in the medical treatment of pain; including misdiagnosis, overprescribing or under prescribing, overdose, abandonment, diversion and vicarious liability.
- Review candidate selection and standard of care monitoring practices for patients taking chronic opioid therapy (COT).
- Learn behavioral strategies to overcome patient resistance to dose change and to encourage buy-in, including gaining comfort with difficult patient interactions around opioid dose changes.
- Master dose reduction schedules and aggressive opioid withdrawal management to promote successful weaning and discontinuation.
|8 am - 12:15 pm||MAT Waiver Training (Non-CME)|
Alison Lynch, MD and Anthony Miller, MD
CDC Prescribing Guidelines
Where Iowa Is At? How We Got Here
|Addiction: A Model|
Thomas Benzoni, DO, EM, AOBEM, FACEP
Innovative Treatment Panel
Pain Management Treatments
The Pain That Won’t Go Away and Strategies for Reducing the Burden
Medical Services Director, United Community Services Healthcare
Thomas Benzoni, DO, EM, AOBEM, FACEP
Assistant Professor, Family Medicine, Des Moines University
Medication Unit Treatment Director, United Community Services Healthcare
Frank Filippelli, DO, PhD
Medical Director, Medication Assisted Treatment, United Community Services Healthcare
Lee Kral, PharmD, BCPS, CPE
Adjunct Assistant Professor in Anesthesia, Adjunct Professor Clinical Pharmacy Practice, Adjunct Assistant Professor of Anesthesia - Chronic Pain Medicine, Adjunct Assistant Professor of Pharmacy Practice and Science, University of Iowa Carver College of Medicine
Heather Kruse, MD
Family Medicine Physician, MercyOne Dubuque Medical Center
Alison Lynch, MD
Clinical Associate Professor, University of Iowa Health Care
Anthony Miller, MD
Director, Medical Student Education, Department of Psychiatry, Staff Psychiatrist, Iowa City Veterans Affairs Medical Center, Clinical Professor of Psychiatry, University of Iowa Carver College of Medicine
Terri Taylor, ARNP
Medication Unit, United Community Services Healthcare
Monica Wilke-Brown, LMSW
Project Director, State Opioid Response, Iowa Department of Public Health
Marylyn Wright, MEd
Opioid Grant Coordinator, Prelude Behavioral Services
Cynthia Woods, DO
Internal Medicine Physician, Crescent Community Health Center
Eric Zacharias, MD
Internal Medicine Physician, Bolder Medical Center, Colorado
Relevant to the content of this educational activity, the planning committee members and speaker indicated they have no financial relationships with commercial interests to disclose.
Continuing Education Credit
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Medical Society. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 5.25 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other Health Professionals: This live activity is designated for a maximum of 5.25 AMA PRA Category 1 Credit(s)™.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 5.25 AOA Category 1A
- 5.25 AMA PRA Category 1 Credits™
- 5.25 CE Contact Hour(s)